EARLY USE IN RUSSIA, ELSEWHERE In addition, the researchers announced that they found no serious side effects from the vaccine. Vaccine name: mRNA-1273 Coronavirus: Brazil is third worst-hit country - but its regions could ease lockdown. With the success of Sinopharm’s BBIBP-CorV vaccine created by Beijing Institute, the fate of the Wuhan candidate was not clear.Updated Dec. 30, PHASE 3 In the spring, the Israel Institute for Biological Research started work on a coronavirus vaccine based on vesicular stomatitis viruses. On Sept. 29, the center and a consortium of German universities registered a Phase 1 trial. On Nov. 13, the company registered a Phase 1 trial to test the safety of the CORVax12.Updated Nov. 13, PRECLINICAL The government rapidly set up clinics across the country where anyone could receive the vaccine. These trials further test the vaccine’s safety. In a Dec. 11 interview, company's chairman Pankaj Patel, the company’s chairman, said the company expects to have their vaccine ready for distribution by March 2021.Updated Jan. 3, PHASE 2 The California-based company Arcturus Therapeutics and Duke-NUS Medical School in Singapore have developed an mRNA vaccine. It is the first clinical trial of a coronavirus vaccine developed in Turkey. The company previously used this technique to make a drug called Zmapp for Ebola. Please authenticate by going to "My account" → "Administration". People who volunteered for the vaccine trial tested positive on HIV antibody tests, even though they were perfectly healthy. Researchers rewrite the genome of viruses, introducing hundreds of mutations. Dose: 2 doses, 3 weeks apart Type: Muscle injection The California-based company ImmunityBio created a vaccine using the Ad5 adenovirus, the same one used by CanSinBio and the Gamaleya Institute in Russia. These ingredients, known as adjuvants, boost the immune system’s response to the coronavirus RBD.Updated Dec. 18, PHASE 1 PHASE 2 COMBINED PHASES Below is a list of all vaccines that have reached trials in humans, along with a selection of promising vaccines being tested in animals. After those studies yielded promising results, Phase 3 testing on 30,000 volunteers began on July 27.On Nov. 16, Moderna announced the first preliminary data from the trial, followed by the complete data on Nov. 30. Vaccines already in use for other diseases that may also protect against Covid-19. Efficacy: 94.5% In August, Arcturus launched a Phase 1/2 trial at Singapore General Hospital. In recent years, the company has tested mRNA vaccines for a number of diseases, but they have yet to bring one to market. Canada-based Medicago, partly funded by the cigarette maker Philip Morris, grow vaccines in a plant called Nicotiana benthamiana, a wild species related to tobacco. On Oct. 14, the TASS news agency reported that clinical trials of the vaccine would begin in Kirov and St. Petersburg on Oct. 19. New, Figures and insights about the advertising and media world, Industry Outlook The full details of the trial have yet to be published in a scientific journal.In an unprecedented move in the coronavirus vaccine field, the Gamaleya Institute joined forces in December with the drugmaker AstraZeneca, which makes a vaccine with human adenoviruses. On June 30, the Japanese biotechnology company AnGes launched a Phase 1 trial to test a DNA-based vaccine, developed in partnership with Osaka University and Takara Bio. They hope the combination will enable the vaccine to produce immunity that’s both fast and long-lasting. Unfortunately, the clamp is similar to a protein on HIV, which can lead the immune system to make HIV-like antibodies. The United States had similar issues with Guam, Puerto Rico, the (U.S.) Virgin Islands and the Northern Mariana Islands. For this statistic, numbers reported by Johns Hopkins University have been compared with the latest available population numbers. Although Johnson & Johnson initially set out to recruit 60,000 volunteers, it capped the trial at 45,000 in December. Although a total of 7,371 volunteers were involved in the trial, the efficacy data was based on only 752 volunteers who got a real vaccine and 570 who received the placebo. Storage: Freezer storage. It contains a part of the spike protein, called RBD, along with two extra ingredients: proteins from a bacteria and aluminum hydroxide. Earlier this year, they engineered the vaccine to produce part of the coronavirus spike protein as well. Researchers at City of Hope, a California biomedical research institute, created a vaccine based on a weakened form of a virus called Modified Vaccinia Ankara, or MVA for short. On Sept. 18 Sanofi closed another deal with the European Union for 300 million doses for an unspecified amount, and later reached an agreement with Canada for up to 72 million doses. In December they launched a Phase 1/2 trial with 345 participants.Updated Dec. 17, PHASE 1 Results are expected in late January. PHASE 3 EFFICACY TRIALS: Scientists give the vaccine to thousands of people and wait to see how many become infected, compared with volunteers who received a placebo. (January 20, 2021). On Nov. 24 they announced the start of a Phase 1 trial, with hopes for a Phase 2 trial to start in the second quarter of 2021.Updated Nov. 24, PHASE 1 Out of the 78 cases of Covid-19 in the trial, 20 were severe — and all 20 were in volunteers who received the placebo. Meanwhile, the trial has continued to gather data. The company has said their total annual manufacturing capacity for the vaccine, if approved, stands at two billion doses.For more details, see How the Oxford-AstraZeneca Vaccine Works.Updated Jan. 19, PHASE 3 It finally launched on Dec. 28.In September, Novavax reached an agreement with the Serum Institute of India, a major vaccine manufacturer, that could enable them to produce as many as 2 billion doses a year. Efficacy: 79.34% Denmark included, for example, numbers for Denmark, Greenland and the Faroe Islands, whereas the Netherlands included numbers for Curacao, Aruba and the Dutch part of Saint Martin. Earlier this year, Vaxart began work on an oral vaccine for Covid-19. That would make the country the first European nation to use a Chinese vaccine.In China, meanwhile, the government gave Sinopharm emergency approval over the summer to inject its vaccine candidates into government officials, health care workers, and other select groups. In 2019, researchers at the University of Hong Kong and Xiamen University created a nasal-spray vaccine for the flu based on a genetically weakened form of the influenza virus. A “team of analysts and researchers” validate the data, the website says. Vaccine name: AG0302-COVID19 ImmunityBio launched a Phase 1 trial of a Covid-19 vaccine in October in the United States. Vaccine name: Sputnik V (also known as Gam-Covid-Vac) On Dec. 26, the makers of Sputnik V tweeted that they had found that the vaccine had an efficacy of over 90 percent in people over 60.In November, the Russian government began offering Sputnik V within Russia in a mass vaccination campaign. On Jan. 3 the Indian government gave Zydus Cadila permission to advance to a Phase 3 trial with 30,000 volunteers. The true toll of the pandemic in the U.S. Vaccine name: Convidecia (also known as Ad5-nCoV) Efficacy: 95% Type: Muscle injection One week ago, the toll was 16,118. Vaccine name: NVX-CoV2373 The virus, which causes the respiratory infection Covid-19, was first detected in the city of Wuhan, China, in late 2019. While AstraZeneca did not comment, the Brazil trial was not paused, suggesting that the volunteer received a placebo. Note: Vaccines will be added to the tracker when they reach Phase 1, and tracked until they succeed or fail. On Oct. 23, the company announced it had reached an agreement with the government of Canada to supply 76 million doses. Type: Muscle injection Other genetic vaccines in active preclinical development include vaccines from: Applied DNA Sciences, EvviVax and Takis Biotech; DIOSynVax; Elixirgen Therapeutics; ETheRNA; Globe Biotech; Greenlight Biosciences; Infectious Disease Research Institute and Amyris; Mediphage Bioceuticals; National institute of Chemistry of Slovenia and Kemijski Inštitut; National Research Centre, Egypt; the OPENCORONA Consortia; Providence Therapeutics; Scancell; the Spanish National Center for Biotechnology and the Spanish National Research Council; Vaccibody.Updated Jan. 14. Dose: Single dose Type: Muscle injection ", Statista, Coronavirus (COVID-19) deaths worldwide per one million population as of January 20, 2021, by country Statista, https://www.statista.com/statistics/1104709/coronavirus-deaths-worldwide-per-million-inhabitants/ (last visited January 20, 2021), Coronavirus (COVID-19) deaths worldwide per one million population as of January 20, 2021, by country, The coronavirus disease (COVID-19) pandemic 2019-20, Infection rates of viruses that caused major outbreaks worldwide as of 2020, Fatality rate of major virus outbreaks in the last 50 years as of 2020, Number of COVID-19 cases and deaths as of January 10, 2021, by region, Distribution of coronavirus (COVID-19) cases worldwide as of January 18, 2021, COVID-19 deaths worldwide per million population as of January 20, 2021, by country, COVID-19 cases, recoveries, deaths in most impacted countries as of Jan. 20, 2021, Rate of COVID-19 cases in most impacted countries worldwide as of Jan. 18, 2021, Coronavirus (COVID-19) in the top 20 economic powers worldwide as of Dec. 8, 2020, COVID-19 cases and deaths among hardest hit countries worldwide as of Jan. 18, 2021, New cases of COVID-19 worldwide from January 23, 2020 to January 19, 2021, by day, Cumulative cases of COVID-19 worldwide from Jan. 22, 2020 to Jan. 19, 2021, by day, COVID-19 projected new cases per day worldwide from Dec. 1-Mar. Because the coronaviruses that cause SARS and Covid-19 are very similar, the researchers revived the project in partnership with the Texas Children’s Hospital. Update, Insights into the world's most important technology markets, Advertising & Media Outlook If daily change is negative, then the dependencies reported new figures earlier than the “main” country; This table shows worldwide countries with a population of one million or more. AstraZeneca registered a Phase 1 trial for the combination on Dec. 24.Since the summer, Russia has negotiated a number of deals to supply other countries with the Sputnik V vaccine, including Brazil, India, Mexico, and Venezuela. In, Statista. Storage: At least a week at room temperature The Chumakov Center at the Russian Academy of Sciences has developed an inactivated coronavirus vaccine. Recently, they’ve tackled influenza and anthrax using this technology. It’s currently the only Western company to be using this traditional method, which is also being pursued in China and India. Moderna has made similar deals with other countries including Canada, Japan, Qatar and South Korea. It carries the gene for the spike protein, which is produced inside cells that it invades. They’ve taken on a number of different diseases this way; their flu vaccine finished Phase 3 clinical trials in March. Experiments on hamsters showed that the vaccine protected them from the coronavirus. Shafa Pharmed Pars, an Iranian pharmaceutical company, developed a vaccine made of inactivated coronaviruses. Vaccines created from weakened coronaviruses or coronaviruses that have been killed with chemicals. See the map, stats, and news for areas affected by COVID-19 on Google News On August 28, their Research Institute for Biological Safety Problems registered a Phase 1 trial on the vaccine, known as QazCovid. Situation by Country, Territory & Area. Please create an employee account to be able to mark statistics as favorites. The company is aiming for production of a billion doses in 2021.On Nov. 16, Johnson & Johnson announced that they were also launching a second Phase 3 trial to observe the effects of two doses of their vaccine, instead of just one.For more details, see How the Johnson & Johnson Vaccine Works.Updated Jan. 14, PHASE 2 When they gave the vaccine to monkeys, they found that it protected the animals from the disease. While Comirnaty caused no serious side effects, it frequently caused short-lived fatigue, fever, and muscle aches.These impressive results led rapidly to authorizations across the world. Shionogi, a Japanese pharmaceutical giant, launched a Phase 1/2 trial of a coronavirus vaccine on Dec. 16. If its clinical trials succeed, Novavax expects to deliver 100 million doses for use in the United States in 2021. Dose: To be determined On Nov. 16, Inovio said that the F.D.A. Type: Muscle injection Vaccine name: CoronaVac (formerly PiCoVacc) On Aug. 24, they launched a Phase 1 trial, and on Nov. 16 they moved to Phase 2.Updated Nov. 20, PHASE 2 If spike proteins are not anchored to a coronavirus, they can unfold. It’s not clear how the trial will fare now that Israel is aggressively vaccinating its citizens with authorized vaccines by Pfizer.Updated Jan. 14, PHASE 1 The vaccine has provided protection in experiments on monkeys. Interactive tools, including maps, epidemic curves and other charts and graphics, with downloadable data, allow users to track and explore the latest trends, numbers and statistics at global, regional and country levels. On Nov. 12, the company announced that its vaccine could be kept in a refrigerator at 41 degrees. Brazilian researchers initially announced that it was above fifty percent, but held off providing further details. The European Union reached a similar deal on Oct. 8 for 200 million doses, and COVAX, an international collaboration to deliver the vaccine equitably across the world, secured 500 million doses. Dose: 2 doses, 3 weeks apart A Phase 1 trial, published in December, did not uncover any serious adverse effects, and measured an immune response all 38 volunteers.Inovio is embroiled in several lawsuits with stockholders and a company partner. Updated Statistics, graphs, and data tables showing the total number of cases, cases per day, cases by country, cases outside of Hubei in China, recoveries and discharges, newly infected, active cases, outcome of closed cases: death rate vs. recovery rate for patients infected with the COVID-19 Coronavirus originating from Wuhan, China They launched a Phase 1 trial at the end of November.Updated Dec. 2, PHASE 1 It also uses aluminum hydroxide as an adjuvant to boost the immune system. To notify The Times of new developments, send updates to vaccinetracker@nytimes.com. the first to put a Covid-19 vaccine into human trials, the effects of two doses of their vaccine, Investments from the Coalition for Epidemic Preparedness, with the European Union for 300 million doses, the first coronavirus vaccine created in India, to develop Covaxin for the United States market, Frequently Asked Questions About the Covid Data. Emergency use in U.S., E.U., other countries. EMERGENCY USE IN BRITAIN, ELSEWHERE Type: Muscle injection It's Statista's policy to update these numbers at least once per day, but we strive to do this more frequently than that. Taiwan-based vaccine maker Medigen is making a vaccine made of a combination of spike proteins and an adjuvant from Dynavax. It was cleared for human testing late last year by the Canadian government. Repurposed vaccines are not included in our vaccine count. In partnership with National Institutes of Health, they found that the vaccine protects monkeys from the coronavirus. authorized the restart of the U.S. trial.On Nov. 19, researchers published the first findings from the Phase 2/3 trials in the United Kingdom. Efficacy: Unknown They launched Phase 2 trials in July, followed by a Phase 3 trial with 29,000 volunteers in December.Updated Dec. 2, PHASE 2 PHASE 3 COMBINED PHASES On Sept. 9, they received approval to start clinical trials in partnership with Beijing Wantai Biological Pharmacy.Updated Sept. 9, PHASE 1 Type: Muscle injection On Aug. 11, the United States government awarded the company an additional $1.5 billion in exchange for 100 million doses if the vaccine proves safe and effective, following up in December with a deal for another 100 million doses in the second quarter of 2021. The company moved ahead with its work in Germany, seeing responses to the vaccine in mice and monkeys before launching clinical trials in July. PHASE 3 On Jan. 3, India followed suit, approving a version called Covishield, made by the Serum Institute of India. Researchers at the Institute of Medical Biology at the Chinese Academy of Medical Sciences, which has invented vaccines for polio and hepatitis A, created an inactivated coronavirus vaccine. Efficacy: Unknown The researchers created the vaccine from a mixture of proteins. Statista. Mexico followed suit the next day. 12 2020, Expected length of COVID-19 outbreak worldwide as Mar. A previous version of the tracker stated that Pfizer had reached a deal with the E.U., when in fact the deal was made by AstraZeneca. On Jan. 8, CureVac announced that it had formed a partnership with pharmaceutical giant Bayer, which would support the vaccine’s development and production.Updated Jan. 12, PHASE 2 PHASE 3 COMBINED PHASES The French pharmaceutical company Sanofi is developing an mRNA vaccine in partnership with Translate Bio. Rallies in Brazil, 20 other countries denounce president’s handling of pandemic amid record number of weekly cases. For consistency, countries with a smaller population (and a potentially much higher impact of coronavirus deaths) were not included in the table. The New York Times reported in December that the administration passed up the chance over the summer to secure another 100 million doses. None of the Phase 3 trial results have yet appeared in a medical journal.Meanwhile, Sinovac has been preparing to manufacture the vaccine for global distribution. In July, the Indian vaccine-maker Zydus Cadila began testing a DNA-based vaccine delivered by a skin patch. The company moved on to a Phase 2/3 trial in December.Updated Dec. 8, PHASE 3 The vaccine is based on a coronavirus protein which is produced in insect cells by genetically altered viruses.Updated Dec. 17, PHASE 1 Causing the body to make extra IL-12 could potentially enhance the immune system’s ability to make antibodies to the spike protein. In April they followed up with a Phase 1/2 trial. Efficacy: Unknown In January, researchers in Brazil announced that it has an overall efficacy of just over 50 percent, the minimum threshold set by many regulatory agencies for authorizing a coronavirus vaccine. A decade ago, researchers at Beth Israel Deaconess Medical Center in Boston developed a method for making vaccines out of a virus called Adenovirus 26, or Ad26 for short. That discovery was enough to cause the Australian government to scrap the trial. They launched a Phase 2 trial on ZyCoV-D on Aug. 6 and announced at the end of December that it was complete. Spain's population, for example, is 46.72 in the table but was 46.723749 in the calculation. But on Dec. 24, the Associated Press reported that volunteers who suspected they had received the placebo were dropping out to receive the vaccine now that it’s widely available. Hence that the "deaths per million" might differ. Donate. After the SARS epidemic in 2002, Baylor College of Medicine researchers began developing a vaccine that could prevent a new outbreak. Latest Yesterday. Type: Muscle injection It also emerged that the low dose was only tried out on volunteers under 55, raising more questions about how strong the preliminary results were. Notes and corrections: Early versions of the tracker combined two vaccines by Sinopharm into one entry, before subsequent reporting confirmed they were two different vaccines. The commission claimed to have tested the vaccine on animals, but provided no data. facts. On Dec. 8, researchers with the University of Oxford and the British-Swedish company AstraZeneca published the first scientific paper on a Phase 3 clinical trial of a coronavirus vaccine. In September they launched a Phase 1 trial.Updated Sept. 15, PHASE 1 That agreement would make Comirnaty the first Western vaccine on track to be sold in China. The company projects the vaccine will become available in Vietnam in mid-2021.Updated Dec. 26, PHASE 1 Dose: 2 doses, 4 weeks apart SpyBiotech, a company spun off from the University of Oxford, announced in September that the first volunteers in an Australian Phase 1/2 trial were receiving their Covid-19 vaccine. Activists angry at Brazil's response to Covid-19 have created 100 graves on Rio's Copacabana beach to remember the more than 40,000 people who have died. Starting in August, CanSino began running Phase 3 trials in a number of countries, including Pakistan, Russia, Mexico and Chile.Updated Dec. 22, PHASE 3 PHASE 1 SAFETY TRIALS: Scientists give the vaccine to a small number of people to test safety and dosage, as well as to confirm that it stimulates the immune system. Vaccine name: INO-4800 Researchers at Thailand’s Chulalongkorn University have been developing several potential vaccines for the coronavirus. Johnson & Johnson began Phase 1/2 trials in July. The European Union signed off on the vaccine on Dec. 21. Type: Muscle injection Brazil authorized CoronaVac on Jan. 17.After creating their vaccine in the spring, Sinovac ran a Phase 1/2 trials on 743 volunteers that revealed no severe adverse effects.